Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, biodistribution, radiation dose and safety of 68Ga-NYM005 PET imaging in healthy volunteers and patients with metastatic clear cell renal cell carcinoma
CTR20241620Phase 2Completed
- Sponsor
- Norroy Bioscience
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NYM005 in clear cell renal cell carcinoma (ccRCC), sponsored by Norroy Bioscience. Started May 2024; status: completed.
02
Drugs
68Ga-NYM005
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20241620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241620.